NCT07149207 2026-03-19
Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors
Medical University of South Carolina
Phase 2 Not yet recruiting
Clinical Trials
1,099 trialsNCT07172256 2026-03-19
CUE-101with Pembrolizumab for LA-HPV+HNSCCs
Yale University
Phase 2 Not yet recruiting
NCT07483359 2026-03-19
CONV3RSION
First Hospital of China Medical University
Phase 2 Not yet recruiting
NCT06258525 2026-03-18
SAMe in Prevention of Oxaliplatin-associated Liver Injury
Cedars-Sinai Medical Center
Phase 2 Not yet recruiting
NCT07472933 2026-03-18
Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies
West China Hospital
Phase 2 Not yet recruiting
NCT07479628 2026-03-18
Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT07480733 2026-03-18
A Phase II Clinical Study Evaluating the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of JS212 andJS213 as Monotherapy and in Combination in Patients Withadvanced Malignant Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Not yet recruiting
NCT07021989 2026-03-17
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
University of California, San Francisco
Phase 2 Not yet recruiting
NCT07322263 2026-03-17
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
Phase 2 Not yet recruiting
NCT07474064 2026-03-17
Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT07476677 2026-03-17
ANDARP
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT07477548 2026-03-17
A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies
Yonsei University
Phase 2 Not yet recruiting
NCT07478523 2026-03-17
FAPDIG
University Hospital, Bordeaux
Phase 2 Not yet recruiting
NCT05479045 2026-03-16
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
Georgetown University
Phase 2 Not yet recruiting
NCT07001995 2026-03-16
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Hunan Province Tumor Hospital
Phase 2 Not yet recruiting
NCT07472478 2026-03-16
GIVEN
Guangdong Provincial People's Hospital
Phase 2 Not yet recruiting
NCT07474558 2026-03-16
SCARLET-ICE
Jules Bordet Institute
Phase 2 Not yet recruiting
NCT05521997 2026-03-13
Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT06930352 2026-03-13
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
Ohio State University Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07322341 2026-03-13
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
University of Washington
Phase 2 Not yet recruiting
NCT07332351 2026-03-13
TRIFECTA
University of Washington
Phase 2 Not yet recruiting
NCT07468916 2026-03-13
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Jonsson Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07469956 2026-03-13
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07470606 2026-03-13
MemoryRT
The University of Texas Health Science Center at San Antonio
Phase 2 Not yet recruiting
NCT07471841 2026-03-13
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Hoosier Cancer Research Network
Phase 2 Not yet recruiting
NCT07466303 2026-03-12
Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Xijing Hospital
Phase 2 Not yet recruiting
NCT07466927 2026-03-12
Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases
Fudan University
Phase 2 Not yet recruiting
NCT07467590 2026-03-12
TRIUNITE-07
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Not yet recruiting
NCT07467772 2026-03-12
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
NCT07077083 2026-03-11
CAIX PET/CT
Massachusetts General Hospital
Phase 2 Not yet recruiting
NCT07164469 2026-03-11
Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07381634 2026-03-11
The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT07441837 2026-03-11
TeLuNa
Ankara University
Phase 2 Not yet recruiting
NCT07455955 2026-03-11
Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile
Chinese University of Hong Kong
Phase 2 Not yet recruiting
NCT07463248 2026-03-11
PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
West China Hospital
Phase 2 Not yet recruiting
NCT07463677 2026-03-11
Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07463768 2026-03-11
MIVONU
French Innovative Leukemia Organisation
Phase 2 Not yet recruiting
NCT07464366 2026-03-11
TSEMPRMSGC
Fudan University
Phase 2 Not yet recruiting
NCT07464756 2026-03-11
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT07465276 2026-03-11
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
NCT07459920 2026-03-10
CAPTURE
National Cancer Institute, Naples
Phase 2 Not yet recruiting
NCT07460206 2026-03-10
PRELUDE
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Not yet recruiting
NCT07460245 2026-03-10
AVESEC
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Not yet recruiting
NCT07460752 2026-03-10
Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients
Mayo Clinic
Phase 2 Not yet recruiting
NCT07462507 2026-03-10
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT07162480 2026-03-09
Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07178912 2026-03-09
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07454915 2026-03-09
PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia
PapiVax Biotech, Inc.
Phase 2 Not yet recruiting
NCT07457177 2026-03-09
Phaes â…¡ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL
Beijing Tongren Hospital
Phase 2 Not yet recruiting
NCT07458113 2026-03-09
BERLIN
Yale University
Phase 2 Not yet recruiting